Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

4625 - Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy

Date

10 Sep 2017

Session

Breast cancer, metastatic

Presenters

Nina Radosevic-Robin

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

N. Radosevic-Robin1, E. Cocco2, H.H. Won3, M.F. Berger3, M. Privat4, C. Abrial5, F. Penault-Llorca1, M. Scaltriti3

Author affiliations

  • 1 Pathology, INSERM 1240, University Clermont Auvergne, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
  • 2 Human Oncology And Pathogenesis Program (hopp), Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 3 Pathology & Human Oncology And Pathogenesis Program (hopp), Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 4 Oncogenetics, INSERM 1240, University Clermont Auvergne, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
  • 5 Clinical Research, INSERM 1240, University Clermont Auvergne, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
More

Resources

Abstract 4625

Background

Most of the clinical trials of EGFR-targeting therapy in triple negative breast cancer (TNBC) were disappointing. Our team has conducted two neoadjuvant trials testing the activity of the anti-EGFR antibodies panitumumab and cetuximab combined with chemotherapy in locally advanced TNBC. We used pre-treatment samples and residual tumours (RT) at surgery to investigate the possible genomic determinants of disease recurrence.

Methods

Tumour tissues sampled before and after neoadjuvant therapy have been analysed by NGS using a targeted exome panel (MSK-IMPACT) of 410 cancer-related genes. The correlations between recurrences and genomic findings were analysed in a case-by-case fashion.

Results

Interpretable data have been obtained for 15 patients (pts) that achieved pathological complete response (pCR) and for 33 that did not. Among the non-pCR pts, 5 presented early fatal metastatic recurrences (EFMR: 1year, < 2 years post-surgery). 23 pts with RT had no recurrences after 5 years post-surgery. Among the 15 pCR pts, only one presented a LNFR (solitary brain metastasis (SBM)). No obvious genomic pattern was predictive of recurrence. Each pts with EFMR had a set of anomalies which will be presented (Pt 1: FGFR2, MLL2, GLI1, RAF1 mutated (mut); Pt 2: no mutations, AKT1, TGFBR2 and TERT loss, SOX9 amplification (amp); Pt 3: KDM6A mut, PTEN loss, MYC amp; Pt 4: PTEN, PIK3CA, ERBB3, ARID1B mut, RAD21, NOTCH2, SOX9 amp; Pt 5: SETD2 mut, HIST2H3D, HIST2H3C, MCL1, EZH2 amp, MAP3K1 loss). Patient with pCR and SBM had BRCA1, MLL2, CDK12 and PPM1D mut, in the pre-therapy sample. In other non-pCR pts various genomic aberrations were detected, including 3 different activating mutations in PIK3CA in one single RT, as well as post-treatment appearance of HRAS G12S mut or PARP1 amp in the non-pCR pts.

Conclusions

This hypothesis-generating study is intended to capture the intrinsic inter-tumour heterogeneity associated with response to EGFR-targeting and chemotherapy in TNBC. These genomic data should be interpreted in the context of other tumour features such as histology, protein and gene expression, immune infiltrates.

Clinical trial identification

NCT00933517 and NCT00600249

Legal entity responsible for the study

Centre Jean Perrin

Funding

Breast Cancer Research Fund

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.